October 21, 2010

HELIX BIOPHARMA CORP. REPORTS POSITIVE EFFICACY AND SAFETY FINDINGS FROM PHASE II STUDY OF ITS TOPICAL INTERFERON ALPHA-2B IN PATIENTS WITH LOW-GRADE CERVICAL LESIONS (PDF)

AURORA, Ontario, October 21, 2010 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical
company developing drug candidates for the prevention and treatment of cancer, today announced positive efficacy and safety findings from its recently completed Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with lowgrade cervical lesions. These findings build upon the positive pharmacokinetic findings from this study announced in the Company’s press release of June 23, 2010.